Basic and clinical studies on FK037 in respiratory infection

H. Fukuhara, J. Inadome, T. Kakazu, H. Nakamura, H. Kaneshima, A. Saito, Nobuchika Kusano, I. Nakasone, Y. Furugen, S. Taira, S. Hokama, M. Tateyama, Y. Irabu, H. Ueji

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We performed basic and clinical studies on FK037, a new parenteral cephalosporin antibiotic, and the following results were obtained. 1) Antimicrobial activity: The minimum inhibitory concentrations (MIC) of FK037 against a total of 302 clinically isolated strains of 13 species were measured and compared with those of five cephalosporins (ceftazidime, flomoxef, ceftizoxime, cefpirome, cefepime) and one carbapenem (imipenem) using the MIC 2000 System (Dynatech Laboratories). FK037 provided a stronger bactericidal activity than ceftazidime, ceftizoxime and cefepime, and equaled to or was stronger than flomoxef and cefpirome in bactericidal activity against gram-positive bacteria, and had stronger bactericidal activity than imipenem, and was equal to or stronger than five cephalosporin antibiotics in bactericidal activity against gram-negative bacteria. FK037 had wide bactericidal activity against these clinical isolated strains except methicillin resistant Staphylococcus aureus. 2) Clinical study results: FK037 was administered to 4 patients with pneumonia in daily doses of 1.0 g to 4.0 g for 7 ~ 15 days by drip infusion. Clinical response was excellent in one, good in one and fair in one except unknown in one patient. No objective or subjective side effects related to the antibiotic were noted. Abnormal laboratory changes were observed in 2 cases, but were transient.

Original languageEnglish
Pages (from-to)227-233
Number of pages7
JournalChemotherapy
Volume42
Issue numberSUPPL. 3
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Respiratory Tract Infections
cefpirome
Cephalosporins
Ceftizoxime
Ceftazidime
Imipenem
Microbial Sensitivity Tests
Carbapenems
Gram-Positive Bacteria
Methicillin-Resistant Staphylococcus aureus
Gram-Negative Bacteria
Intravenous Infusions
Pneumonia
Clinical Studies
cefoselis
Anti-Bacterial Agents
cefepime
flomoxef

ASJC Scopus subject areas

  • Pharmacology

Cite this

Fukuhara, H., Inadome, J., Kakazu, T., Nakamura, H., Kaneshima, H., Saito, A., ... Ueji, H. (1994). Basic and clinical studies on FK037 in respiratory infection. Chemotherapy, 42(SUPPL. 3), 227-233.

Basic and clinical studies on FK037 in respiratory infection. / Fukuhara, H.; Inadome, J.; Kakazu, T.; Nakamura, H.; Kaneshima, H.; Saito, A.; Kusano, Nobuchika; Nakasone, I.; Furugen, Y.; Taira, S.; Hokama, S.; Tateyama, M.; Irabu, Y.; Ueji, H.

In: Chemotherapy, Vol. 42, No. SUPPL. 3, 1994, p. 227-233.

Research output: Contribution to journalArticle

Fukuhara, H, Inadome, J, Kakazu, T, Nakamura, H, Kaneshima, H, Saito, A, Kusano, N, Nakasone, I, Furugen, Y, Taira, S, Hokama, S, Tateyama, M, Irabu, Y & Ueji, H 1994, 'Basic and clinical studies on FK037 in respiratory infection', Chemotherapy, vol. 42, no. SUPPL. 3, pp. 227-233.
Fukuhara H, Inadome J, Kakazu T, Nakamura H, Kaneshima H, Saito A et al. Basic and clinical studies on FK037 in respiratory infection. Chemotherapy. 1994;42(SUPPL. 3):227-233.
Fukuhara, H. ; Inadome, J. ; Kakazu, T. ; Nakamura, H. ; Kaneshima, H. ; Saito, A. ; Kusano, Nobuchika ; Nakasone, I. ; Furugen, Y. ; Taira, S. ; Hokama, S. ; Tateyama, M. ; Irabu, Y. ; Ueji, H. / Basic and clinical studies on FK037 in respiratory infection. In: Chemotherapy. 1994 ; Vol. 42, No. SUPPL. 3. pp. 227-233.
@article{b45687cc94564e2e818b2e8fdf991466,
title = "Basic and clinical studies on FK037 in respiratory infection",
abstract = "We performed basic and clinical studies on FK037, a new parenteral cephalosporin antibiotic, and the following results were obtained. 1) Antimicrobial activity: The minimum inhibitory concentrations (MIC) of FK037 against a total of 302 clinically isolated strains of 13 species were measured and compared with those of five cephalosporins (ceftazidime, flomoxef, ceftizoxime, cefpirome, cefepime) and one carbapenem (imipenem) using the MIC 2000 System (Dynatech Laboratories). FK037 provided a stronger bactericidal activity than ceftazidime, ceftizoxime and cefepime, and equaled to or was stronger than flomoxef and cefpirome in bactericidal activity against gram-positive bacteria, and had stronger bactericidal activity than imipenem, and was equal to or stronger than five cephalosporin antibiotics in bactericidal activity against gram-negative bacteria. FK037 had wide bactericidal activity against these clinical isolated strains except methicillin resistant Staphylococcus aureus. 2) Clinical study results: FK037 was administered to 4 patients with pneumonia in daily doses of 1.0 g to 4.0 g for 7 ~ 15 days by drip infusion. Clinical response was excellent in one, good in one and fair in one except unknown in one patient. No objective or subjective side effects related to the antibiotic were noted. Abnormal laboratory changes were observed in 2 cases, but were transient.",
author = "H. Fukuhara and J. Inadome and T. Kakazu and H. Nakamura and H. Kaneshima and A. Saito and Nobuchika Kusano and I. Nakasone and Y. Furugen and S. Taira and S. Hokama and M. Tateyama and Y. Irabu and H. Ueji",
year = "1994",
language = "English",
volume = "42",
pages = "227--233",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Basic and clinical studies on FK037 in respiratory infection

AU - Fukuhara, H.

AU - Inadome, J.

AU - Kakazu, T.

AU - Nakamura, H.

AU - Kaneshima, H.

AU - Saito, A.

AU - Kusano, Nobuchika

AU - Nakasone, I.

AU - Furugen, Y.

AU - Taira, S.

AU - Hokama, S.

AU - Tateyama, M.

AU - Irabu, Y.

AU - Ueji, H.

PY - 1994

Y1 - 1994

N2 - We performed basic and clinical studies on FK037, a new parenteral cephalosporin antibiotic, and the following results were obtained. 1) Antimicrobial activity: The minimum inhibitory concentrations (MIC) of FK037 against a total of 302 clinically isolated strains of 13 species were measured and compared with those of five cephalosporins (ceftazidime, flomoxef, ceftizoxime, cefpirome, cefepime) and one carbapenem (imipenem) using the MIC 2000 System (Dynatech Laboratories). FK037 provided a stronger bactericidal activity than ceftazidime, ceftizoxime and cefepime, and equaled to or was stronger than flomoxef and cefpirome in bactericidal activity against gram-positive bacteria, and had stronger bactericidal activity than imipenem, and was equal to or stronger than five cephalosporin antibiotics in bactericidal activity against gram-negative bacteria. FK037 had wide bactericidal activity against these clinical isolated strains except methicillin resistant Staphylococcus aureus. 2) Clinical study results: FK037 was administered to 4 patients with pneumonia in daily doses of 1.0 g to 4.0 g for 7 ~ 15 days by drip infusion. Clinical response was excellent in one, good in one and fair in one except unknown in one patient. No objective or subjective side effects related to the antibiotic were noted. Abnormal laboratory changes were observed in 2 cases, but were transient.

AB - We performed basic and clinical studies on FK037, a new parenteral cephalosporin antibiotic, and the following results were obtained. 1) Antimicrobial activity: The minimum inhibitory concentrations (MIC) of FK037 against a total of 302 clinically isolated strains of 13 species were measured and compared with those of five cephalosporins (ceftazidime, flomoxef, ceftizoxime, cefpirome, cefepime) and one carbapenem (imipenem) using the MIC 2000 System (Dynatech Laboratories). FK037 provided a stronger bactericidal activity than ceftazidime, ceftizoxime and cefepime, and equaled to or was stronger than flomoxef and cefpirome in bactericidal activity against gram-positive bacteria, and had stronger bactericidal activity than imipenem, and was equal to or stronger than five cephalosporin antibiotics in bactericidal activity against gram-negative bacteria. FK037 had wide bactericidal activity against these clinical isolated strains except methicillin resistant Staphylococcus aureus. 2) Clinical study results: FK037 was administered to 4 patients with pneumonia in daily doses of 1.0 g to 4.0 g for 7 ~ 15 days by drip infusion. Clinical response was excellent in one, good in one and fair in one except unknown in one patient. No objective or subjective side effects related to the antibiotic were noted. Abnormal laboratory changes were observed in 2 cases, but were transient.

UR - http://www.scopus.com/inward/record.url?scp=0028127043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028127043&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028127043

VL - 42

SP - 227

EP - 233

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

IS - SUPPL. 3

ER -